2025/04/10 by Andrew A. Almonte, Simon Thomas, Laurence Zitvogel · 1 voice
Biochemistry, Genetics and Molecular Biology · Medicine · #Cancer Immunotherapy and Biomarkers #Clostridium difficile and Clostridium perfringens research #Gut microbiota and health
paper · doi:10.1084/jem.20250378
openalex publication_date 2025/04/10 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/31
Immune checkpoint blockade therapies have markedly advanced cancer treatment by invigorating antitumor immunity and extending patient survival. However, therapeutic resistance and immune-related toxicities remain major concerns. Emerging evidence indicates that microbial dysbiosis diminishes therapeutic response rates, while a diverse gut ecology and key beneficial taxa correlate with improved treatment outcomes. Therefore, there is a growing understanding that manipulating the gut microbiota could boost therapy efficacy. This review examines burgeoning methods that target the gut microbiome to optimize therapy and innovative diagnostic tools to detect dysbiosis, and highlights challenges that remain to be addressed in the field.